As more international markets begin paying attention to Chinese pharmaceuticals, Chinese generic drugs have become an increasingly important topic in global pharmaceutical procurement.

However, many concerns still remain:

● Are Chinese generic drugs reliable?

● Which medicines can be safely substituted?

● Which therapies still require caution?

● What are the real differences between original drugs and generics?

In reality, not all medicines are suitable for simple substitution.

Different diseases, drug categories, and treatment stages require very different approaches to generic substitution.

Especially in oncology, rare diseases, and major chronic disease treatment, drug selection affects not only therapeutic outcomes, but also the long-term sustainability of treatment.

In this article, Chinese pharmaceutical wholesaler DengYueMed explains the differences between original drugs and Chinese generics, as well as which medicines may be relatively suitable for substitution and which areas still require more careful evaluation.

What Are Original Drugs and Generic Drugs?

Original Drugs

Original drugs refer to medicines that were first developed, clinically tested, and approved for marketing.

These products typically involve:

● Long-term research and development

● Large-scale clinical trials

● Global regulatory approvals

● Significant R&D investment

Many internationally recognized oncology drugs, targeted therapies, and rare disease medicines belong to this category.

The main advantages of original drugs usually include:

● Comprehensive clinical data

● Extensive global usage experience

● More long-term safety data

● Higher physician familiarity

However, these products are also often significantly more expensive.

Generic Drugs

Generic drugs are medicines manufactured by other companies after the patent protection of the original drug expires.

In theory, qualified generics are required to demonstrate:

● The same active pharmaceutical ingredient (API)

● The same dosage strength

● The same route of administration

● Comparable bioavailability

However, it is important to understand that:

“Generic drug” does not mean that all products are identical in quality.

There may be significant differences between countries, manufacturers, and production systems.

This is why many overseas buyers and healthcare professionals are not simply asking whether Chinese generics exist, but rather whether Chinese generics are truly reliable.

Chinese Generic Drugs Have Entered a New Stage

Many people still associate Chinese generics with perceptions from more than a decade ago.

However, China’s pharmaceutical regulatory system has undergone major changes in recent years.

Particularly in the following areas:

● GMP manufacturing standards

● Bioequivalence (BE)

● Generic consistency evaluation

● Drug quality supervision

● Marketing Authorization Holder (MAH) system

China has gradually aligned many aspects of its pharmaceutical system with international standards.

What Is Generic Consistency Evaluation?

This is one of the most important concepts for international pharmaceutical procurement.

Simply put, generic drugs that pass consistency evaluation are required to demonstrate pharmacokinetic performance comparable to the original drug.

This includes:

● Absorption rate

● Blood concentration levels

● Systemic drug exposure

For many mature small-molecule drugs, this process has significantly improved the reliability of generic products.

As a result, high-quality Chinese generics are now widely used in many major hospitals across China.

This is one of the key reasons why more international markets are beginning to reassess China’s pharmaceutical industry.

Which Medicines Can Usually Be Substituted More Safely?

Not all drugs are suitable for substitution.

However, for certain mature products, high-quality Chinese generics have already demonstrated strong clinical accessibility and cost advantages.

1. Mature Small-Molecule Targeted Therapies

This is currently one of the most mature areas for generic substitution in China.

Examples include:

● Imatinib

● Gefitinib

● Erlotinib

● Lenalidomide

● Apixaban

● Rivaroxaban

Many of these products already have:

● Mature manufacturing processes

● Large-scale clinical usage experience

● Established BE data

● Stable supply systems

For long-term treatment settings, the value of high-quality generics is not only lower pricing, but also the ability to support sustainable long-term treatment access.

Especially in long-term oncology maintenance therapy, drug accessibility itself is critically important.

2. Long-Term Chronic Disease Therapies

The same applies to certain long-term treatments for hypertension, diabetes, and anticoagulation therapy.

In these areas, the key issue is often not short-term efficacy alone, but whether treatment can remain:

● Stable

● Sustainable

● Affordable over many years

In such cases, high-quality generics often provide significant practical value.

Which Medicines Still Require Greater Caution?

Professional pharmaceutical evaluation is not about claiming that “everything can be substituted,” but rather understanding which products require greater caution.

1. Biologics

This is one of the most sensitive areas for substitution.

Examples include:

● PD-1 / PD-L1 inhibitors

● Monoclonal antibodies

● Bispecific antibodies

● ADCs (Antibody-Drug Conjugates)

● Recombinant proteins

● Certain biologics for rare diseases

These products are structurally highly complex.

Even when the mechanism of action is similar, differences in:

● Cell lines

● Fermentation processes

● Purification methods

● Stability control

may affect the final clinical performance of the product.

Therefore, biosimilars are not identical copies of the original biologic.

In many situations, healthcare professionals still pay close attention to:

● Long-term clinical data

● Immunogenicity risks

● Individual patient response

● Long-term follow-up data

This is why original biologics still maintain strong advantages in some advanced therapeutic areas.

2. Narrow Therapeutic Index (NTI) Drugs

Some drugs are extremely sensitive to fluctuations in blood concentration levels.

Examples include:

● Certain antiepileptic drugs

● Warfarin

● Immunosuppressants

● Transplant-related medications

Even small variations may affect efficacy or safety.

For this reason, frequent manufacturer switching is generally not recommended in clinical practice.

If substitution is necessary, additional monitoring is often required.

3. Modified-Release Formulations and Complex Drug Delivery Systems

Some modified-release formulations and complex delivery systems cannot simply be considered equivalent because they contain the same ingredient.

Examples include:

● Extended-release pain medications

● Liposomal formulations

● Specialized controlled-release systems

Because drug release profiles themselves may directly affect both efficacy and adverse reactions.

What Should Really Be Considered When Comparing Original Drugs and Generics?

For international markets, the real question is not simply:

● “Are original drugs always better?”

● “Can generics completely replace original drugs?”

The more important question is:

Which option is most appropriate for a specific disease, treatment stage, and market demand?

In real-world clinical and supply settings:

● Some medicines already support relatively mature generic substitution

● Other areas still require more careful evaluation of substitution risks

Mature procurement and supply decisions usually require consideration of:

● Disease category

● Drug type

● Clinical maturity

● Quality systems

● Long-term supply stability

● Market demand

All of these factors are important.

How Does DengYueMed Support International Pharmaceutical Supply?

For many international partners, the real challenge is often not identifying the drug itself, but evaluating:

● Which manufacturers are more reliable?

● Which products already have broad clinical usage?

● Which medicines are suitable for substitution?

● Which areas still favor original drugs?

As a China-based pharmaceutical wholesaler serving international markets, DengYueMed mainly focuses on:

● Oncology drugs

● Rare disease medicines

● Major chronic disease therapies

We provide:

● Original drugs

● High-quality Chinese generics

● Selected biosimilar products

Based on different market needs, we also support:

● Pharmaceutical information matching

● Product sourcing and selection

● Supply chain support

● Long-term supply cooperation

Conclusion

The comparison between original drugs and generic drugs is not simply about which one is “better.”

What truly matters is the specific product, the manufacturer’s quality system, and whether the medicine is appropriate for the intended treatment setting.

As China’s pharmaceutical industry and regulatory system continue to evolve, an increasing number of high-quality Chinese generics have demonstrated mature clinical application and international supply capability. At the same time, certain highly complex therapeutic areas still require more cautious evaluation of substitution risks.

For international markets, establishing a stable, compliant, and reliable pharmaceutical supply system is often far more important than price advantage alone.